PDE5A and hypogonadism: Given that combination treatment with PDE5 inhibitors and testosterone is safe and effective compared to monotherapy of PDE5 inhibitors (Spitzer et al., 2012), it may be advised to initially prefer combination therapy with testosterone and PDE5 inhibitors in patients with hypogonadism (Tsertsvadze et al., 2009).